CNS Pharmaceuticals, Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2017 | — | $-58.5K | $110.5K |
| Mar 2018 | — | $35.0K | — |
| Jun 2018 | — | $-197.8K | — |
| Sep 2018 | — | $-347.0K | $708.6K |
| Dec 2018 | — | $-549.3K | $282.7K |
| Mar 2019 | — | $-716.8K | $155.0K |
| Jun 2019 | — | $377.7K | $911.9K |
| Sep 2019 | — | $216 | $630.1K |
| Dec 2019 | — | $7.6M | $7.2M |
| Mar 2020 | — | $5.9M | $5.4M |
| Jun 2020 | — | $3.7M | $2.6M |
| Sep 2020 | — | $2.5M | $1.3M |
| Dec 2020 | — | $13.9M | $14.0M |
| Mar 2021 | — | $11.2M | $11.1M |
| Jun 2021 | — | $12.4M | $6.9M |
| Sep 2021 | — | $9.1M | $8.3M |
| Dec 2021 | — | $6.2M | $5.0M |
| Mar 2022 | — | $14.0M | $12.4M |
| Jun 2022 | — | $10.7M | $9.0M |
| Sep 2022 | — | $7.6M | $7.0M |
| Dec 2022 | — | $8.1M | $10.1M |
| Mar 2023 | — | $3.5M | $5.1M |
| Jun 2023 | — | $2.5M | $4.3M |
| Sep 2023 | — | $-1.7M | $909.5K |
| Dec 2023 | — | $-4.4M | $548.7K |
| Mar 2024 | — | $-4.4M | $815.2K |
| Jun 2024 | — | $-4.3M | $1.5M |
| Sep 2024 | — | $3.4M | $7.0M |
| Dec 2024 | — | $6.2M | $6.5M |
| Mar 2025 | — | $11.0M | $13.0M |
| Jun 2025 | — | $13.1M | $12.1M |
| Sep 2025 | — | $9.9M | $9.9M |
| Dec 2025 | — | $4.5M | $7.2M |
| Mar 2026 | — | $71.0K | $3.0M |
| Jun 2026 | — | $18.2M | $20.0M |